Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization

Journal of Cardiovascular Medicine

Volumn 9, Issue 12, 2008, Pages 1274-1278

  Cevik, Cihan ^a   Otahbachi, Mohammad ^a   Nugent, Kenneth ^a   Warangkana, Chokesuwattanaskul ^a   Meyerrose, Gary ^a  

^a TEXAS TECH UNIVERSITY   (United States)

Author keywords

Acute coronary syndrome; Atherosclerosis; Matrix metalloproteinases; Statin

Indexed keywords

COLLAGENASE 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ROSUVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; BLOOD;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MATRIX METALLOPROTEINASE 13; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 59449085994     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328316912f     Document Type: Article

References (22)

1. Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998; 97:2433-2444.
2. Sukhova GK, Schönbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, et al. Evidence for increased collagenolysis by interstitial collagenases1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99:2503-2509.
3. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001; 104:1899-1904.
4. Inoue T, Kato T, Takayanagi K, Uchida T, Yaguchi I, Kamishirado H, et al. Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome. Am J Cardiol 2003; 92:1461-1464.
5. Dabek J, Kulach A, Gasior Z. The role of matrix metalloproteinases in acute coronary syndromes. Eur J Intern Med 2007; 18:463-466.
6. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, et al. HMG-CoA Reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Bio 1998; 18:1671-1678.
7. Kalela A, Laaksonen R, Lehtimäki T, Koivu TA, Hö yhtyä M, Janatuinen T, et al. Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. Am J Car 2001; 88:173-175.
8. Deguchi JO, Aikawa E, Libby P, Vachon JR, Inada M,Krane SM, et al. Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation 2005; 112:2708-2715.
9. Hernandez TL, Capell WH, Wolfe P, Gerard LA, Eckel RH. Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus. Am J Cardiol 2006; 98:1656-1659.
10. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al., Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285:1711-1718.
11. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al., Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
12. Li JJ, Wang Y, Nie SP, Zhang CY, Li YS, Hui RT, et al. Reduction of C-reactive protein by a single 80 mg of simvastatin in patients with unstable angina. Clin Chim Acta 2007; 376:163-167.
13. van der Meer IM, de Maat MP, Kiliaan AJ, van der Kuip DA, Hofman A, Witteman JC. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med 2003; 163:1323-1328.
14. Suzuki H, Kusuyama T, Sato R, Yokota Y, Tsunoda F, Sato T, etal. Elevation of matrix metalloproteinases and interleukin-6 in the culprit coronary artery of myocardial infarction. Eur J Clin Invest 2008; 38:166-173.
15. Prinz V, Laufs U, Gertz K, Kronenberg G, Balkaya M, Leithner C, et al. Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke 2008; 39:433-438.
16. Huang CY, Wu TC, Lin WT, Leu HB, Lin CP, Lin SJ, Chen JW. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients. Eur J Clin Invest 2006; 36:76-84.
17. McGowan MP. There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation 2004; 110:2333-2335.
18. Waters DD, Guyton JR, Herrington DM, et al. Treating to New Targets (TNT) Study: does lowering low density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2003; 93:154-158.
19. Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD, Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105:1446-1452.
20. Heeschen C, Hamm CW, Laufs U, Böhm M, Snapinn S, White HD. Withdrawal of statins in patients with acute coronary syndromes. Circulation 2003; 107:e27.
21. PRISM Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina: Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998; 338:1498-1505.
22. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al., ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295:1556-1565.